SEARCH

SEARCH BY CITATION

Keywords:

  • Wilms' tumor;
  • Kenya;
  • Africa;
  • β-catenin;
  • WT1;
  • imaging mass spectrometry

Abstract

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Sub-Saharan African children have an increased incidence of Wilms' tumor (WT) and experience alarmingly poor outcomes. Although these outcomes are largely due to inadequate therapy, we hypothesized that WT from this region exhibits features of biological aggressiveness that may warrant broader implementation of high-risk therapeutic protocols. We evaluated 15 Kenyan WT (KWT) for features of aggressive disease (blastemal predominance and Ki67/cellular proliferation) and treatment resistance (anaplasia and p53 immunopositivity). To explore the additional biological features of KWT, we determined the mutational status of the CTNNB1/β-catenin and WT1 genes and performed immunostaining for markers of Wnt pathway activation (β-catenin) and nephronic progenitor cell self-renewal (WT1, CITED1 and SIX2). We characterized the proteome of KWT using imaging mass spectrometry (IMS). The results were compared to histology- and age-matched North American WT (NAWT) controls. For patients with KWT, blastemal predominance was noted in 53.3% and anaplasia in 13%. We detected increased loss to follow-up (p = 0.028), disease relapse (p = 0.044), mortality (p = 0.001) and nuclear unrest (p = 0.001) in patients with KWT compared to controls. KWT and NAWT showed similar Ki67/cellular proliferation. We detected an increased proportion of epithelial nuclear β-catenin in KWT (p = 0.013). All 15 KWT specimens were found to harbor wild-type CTNNB1/β-catenin, and one contained a WT1 nonsense mutation. WT1 was detected by immunostaining in 100% of KWT, CITED1 in 80% and SIX2 in 80%. IMS revealed a molecular signature unique to KWT that was distinct from NAWT. The African WT specimens appear to express markers of adverse clinical behavior and treatment resistance and may require alternative therapies or implementation of high-risk treatment protocols.

Wilms' tumor (WT) is the most common childhood kidney cancer worldwide, yet its incidence and behavior vary between ethnic groups.1–3 Children residing in resource-constrained regions of sub-Saharan Africa experience high incidence rates of WT and alarmingly dismal outcomes. Compared to 4-year overall survival rates exceeding 90% in developed countries, certain developing nations in sub-Saharan Africa achieve only a 2-year relapse-free survival rate of 35-40%.4–8 Presentation with advanced stages of disease, severe anemia and acute malnutrition are common among patients with WT from this region, complicating adequate treatment and rendering recipients of chemotherapy considerably more vulnerable to treatment toxicities.9 Although much of this poor survival can be attributed to inadequate healthcare resources and incomplete delivery of standard WT therapies, the contribution of unique biological properties to the high incidence and adverse behavior of WT within these vulnerable populations has not been previously reported.

Several histologic features of WT have been associated with adverse behavior and treatment resistance. Anaplasia (unfavorable histology) is defined by the presence of multipolar mitoses, hyperchromatic nuclei and nuclear gigantism. Although present in only 5% of WT, anaplasia accounts for half of WT-associated deaths in developed countries.10–12 Anaplasia can be present in all stages of WT and is, therefore, not directly associated with tumor aggressiveness; however, it is strongly associated with treatment resistance.13 In contrast, blastemal predominance in WT has been associated with significant aggressiveness (i.e., advanced stage of disease); however, these tumors are typically responsive to initial therapy.13 Nuclear unrest, or the presence of abnormally large and hyperchromatic nuclei without multipolar mitoses, has been described as a potential intermediate step in the degeneration from favorable to unfavorable histology (anaplasia).14 Nuclear unrest has been observed to appear in WT specimens from disease relapse (in some cases accompanied by anaplasia as well); however, the direct clinical significance of this observation is unclear.14

Several tumor markers have been identified in WT that associate with adverse clinical disease features. Accumulation of the tumor suppressor protein, p53, in WT specimens has been associated with anaplasia and treatment resistance.15–17 A proliferative index greater than 5% in WT specimens, as defined by percent positive Ki67 staining nuclei, has also been associated with greatly increased disease progression and decreased tumor-specific survival.18

Wilms' tumorigenesis stems from dysregulation of pathways critical to normal kidney development. β-Catenin, the protein product of the CTNNB1 gene, is involved in cadherin-mediated cell adhesion and the Wnt signaling pathway. In WT, as in other cancers, nuclear localization of β-catenin has been shown to signify either Wnt pathway activation or mutations that stabilize β-catenin itself.19, 20 β-catenin mutations cluster at exon 3 of the CTNNB1 gene, which codes for critical amino acid residues that regulate its nuclear localization and transcriptional activity on phosphorylation.21 Wnt pathway activation and nuclear localization of β-catenin have been implicated as key features of tumorigenesis in a rat nephroblastoma model.22 β-Catenin mutations and upregulation of β-catenin target genes have been associated with WT1-mutant WT. Dysregulated β-catenin activation in the context of absent WT1 tumor suppression is thought to represent a critical tumorigenic step in this WT subpopulation.23 In WT, CTNNB1 mutations in exons 7 and 8 have been shown to cluster with mutations in the WTX gene, whereas CTNNB1 mutations in exon 3 cluster with mutations in WT1.24, 25 WTX is an associated protein involved in the Wnt signaling pathway that is responsible for ubiquitination and degradation of β-catenin.26 It is estimated that one-third of WT possess mutations in WT1, WTX and/or CTNNB1/β-catenin.27

WTs are postulated to arise from persistence of nephronic progenitor cells, comprising the metanephric mesenchyme (MM) of the embryonic kidney, which have escaped pathways of epithelial differentiation.28 WT1, CITED1 and SIX2 are genes active in the MM that are downregulated in fated cells undergoing epithelial differentiation.29–32 Although the self-renewing component of the MM is defined by CITED1+SIX2+ cells, only SIX2 has been shown to directly regulate self-renewal.31 In late gestation, when the MM has fully differentiated and is no longer present, WT1 expression persists in podocytes and epithelial cells of Bowman's capsule, whereas CITED1 and SIX2 are not expressed and remain inactive in the postnatal kidney.33 Loss of heterozygosity of WT1 has been identified in a small, but significant, proportion of patients with WT and leads to nephrogenic rests, a WT precursor lesion defined as abnormal persistence of nephronic progenitor cells.27, 34 We have previously published that CITED1 remains active in both WT and nephrogenic rests and associates with advanced stages of disease in favorable histology WT.35 SIX2 expression parallels CITED1 closely both in development and in a broad spectrum of WT.47

Although a number of poor prognostic markers have been characterized in WT, the use of high-throughput proteomic analysis allows for molecular characterization of aggressive tumors or high-risk populations beyond described markers. Matrix-assisted laser desorption ionization time of flight imaging mass spectrometry (IMS) has been recently shown to be an innovative, high-throughput means to analyze the proteome of formalin-fixed paraffin-embedded (FFPE) tissues, the only currently available means of tissue preservation in resource-constrained regions of sub-Saharan Africa.36 This tool enables the characterization of high-risk molecular signatures, as well as the potential discovery of novel therapeutic targets. We have recently characterized the proteome of stage- and histology-matched North American WT (NAWT) tissues using IMS,37 and in our study, we compare our established signature to that of WT from sub-Saharan Africa.

Although much of the poor outcomes for patients with WT residing in resource-constrained regions of sub-Saharan Africa can be attributed to inadequate access to therapy, we hypothesized that WT from these regions show evidence of more biologically aggressive disease, warranting therapy designed for high-risk categories. In addition, given the high incidence of WT in Africa, we questioned whether these patients exhibit unique disease biology on the proteomic level compared to patients with NAWT.

Material and Methods

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Acquisition of WT specimens and epidemiologic data

A surgical resident in our laboratory traveled to Kenya to query the electronic records of all patients with WT treated from January 1, 1992 to July 1, 2010 at a faith-based mission hospital in Kenya. This mission hospital also provides regional pathology services to healthcare facilities in eastern Africa.

A total of 60 patients with WT were identified, and 21 had available FFPE tissue specimens. The available patient specimens originated from five different hospitals in this region. Regardless of treating institution, the medical records were absent or incomplete because of patient loss to follow-up in nearly every case. When possible, Children's Oncology Group (COG) criteria were used to stage patients based on pathologic characteristics and clinical details.10 When complete clinical details were not available, a minimum stage was calculated using COG criteria based on the pathology report alone.

A control group of 20 patient specimens with NAWT was assembled from our institutional pathology archives. This control group contained 10 consecutive Black and White patients treated at our institution, respectively. NAWT controls were matched to the Kenyan WT (KWT) specimens in terms of patient age, gender and percentage of unfavorable histology; however, we could not match the controls exactly stage-for-stage to the KWT specimens because of incomplete clinical data from Africa. Experiments were conducted according to the ethical standards for human subjects research from the Vanderbilt University Institutional Review Board (study numbers 020888 and 100734) and the Kijabe Mission Hospital Ethics Committee.

Pathologic review of acquired specimens

A dedicated, board-certified pediatric pathologist reviewed all acquired KWT and NAWT specimens. For KWT, we received 70 total tissue blocks from 21 patients, with 67 tissue blocks requiring deparaffinization and re-embedding. Because of significant tumor necrosis on hematoxylin and eosin (H&E) staining, tissue blocks from six patients were excluded from further analysis.

The 15 remaining specimens were reviewed and assessed for integrity of tissue fixation, diagnosis, favorable or unfavorable histology (diffuse anaplasia), triphasic histology and cellular predominance. No fresh tissue specimens were available for molecular analysis.

Immunohistochemistry

To characterize the expression of p53, Ki67, β-catenin, WT1, CITED1 and SIX2 in KWT, we performed immunoperoxidase staining of the aforementioned 15 FFPE KWT tissues. All samples were subjected to heat-induced epitope retrieval in 10 mM of citrate buffer. As described previously, 5-μm sections were incubated in affinity-purified rabbit anti-CITED1 (1:50 dilution; Lab Vision Corp., Fremont, CA) or rabbit anti-SIX2 (1:25 dilution; US Biological Corp., Marblehead, MA) for 1 hr at room temperature.35 Goat-anti-rabbit secondary antibody (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) was applied to tissues at room temperature for 45 min. Tissues were visualized with a Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Tissues were similarly incubated in rabbit anti-β-catenin (1:50 dilution; Cell Signaling, Danvers, MA), rabbit anti-WT1 (1:500 dilution; Santa Cruz) or rabbit anti-p53 (1:50 dilution; Cell Signaling) overnight at 4°C. Tissues were then visualized with an anti-rabbit Dako EnVision kit (DakoCytomation, Carpinteria, CA). For Ki67, the sections were rehydrated and placed in heated Target Retrieval Solution (Lab Vision Corp.). Endogenous peroxidase was neutralized with 0.03% of hydrogen peroxide followed by a casein-based protein block (DakoCytomation) to minimize nonspecific staining. The sections were incubated with Ki67 (Catalog #VP-K451; Vector Laboratories) diluted in 1:2,000 for 60 min. The Dako Envision+ HRP/DAB System (DakoCytomation) was used to produce localized visible staining.

Positive immunostaining was defined as either crisp nuclear or cytoplasmic immunoperoxidase positivity by light microscopy. For Ki67, a marker of cellular proliferation, Photoshop software (Adobe, San Jose, CA) was used to quantify the percent area of immunoperoxidase positivity relative to the total area of nuclei per slide. A proliferative index was estimated and defined as the percent positive staining Ki67 cells averaged over five high-power fields (×400 magnification). The counting of individual Ki67-labeled cells was deemed imprecise because of the inability to distinguish one nucleus from another because of high cellular density in blastemal predominant regions.

Characterization of β-catenin and WT1 mutations in Kenyan specimens

To characterize the mutational status of β-catenin and WT1 in KWT specimens, we sequenced exons 3, 7 and 8 of CTNNB1 gene and exons 2–10 of WT1 using previously described techniques.20, 25, 38–40 Given the critical importance of phosphorylation residues in CTNNB1 exon 3 on Wnt signaling pathway activation, analysis of exon 3 was conducted using two previously described primer sets.20, 25 All PCR and sequencing primer sequences are available on request and are also included in the Supporting Information. Briefly, four 10-μm paraffin-embedded sections from each KWT specimen were deparaffinized and digested in proteinase K (Qiagen, Germantown, MD) for 12 hr. Genomic DNA was isolated using a QIAamp DNA FFPE tissue kit (Qiagen). From isolated genomic DNA, we amplified the aforementioned exons of the CTNNB1 and WT1 genes using PCR with Taq DNA polymerase (Sigma-Aldrich, St. Louis, MO). PCR products were gel purified using a QIAquick gel extraction kit (Qiagen) and subsequently directly sequenced using BigDye Terminator chemistry (Applied Biosystems, Foster City, CA) resolved on an ABI 3730 DNA Analyzer (Applied Biosystems). Generated sequences and chromatographs were compared to wild-type CTNNB1 and WT1 sequences using the Basic Local Alignment Search Tool (BLAST; NCBI, Bethesda, MD) to determine the mutational status of each specimen. Suspected mutations were confirmed by repeating both the PCR and the sequencing reactions. Base-pair references are made with respect to sequence NM_001098209.1 for CTNNB1 and NM_000378.4 (WT protein isoform A) for WT1.

Imaging mass spectrometry

To identify unique biological features of KWT, we compared the proteome of these specimens to previously characterized ethnic-specific WT signatures.37 Using IMS as previously described,36, 41 we analyzed a single tissue section from each of two distinct specimen blocks from five KWT specimens. Two 6-μm serial sections from each specimen block were cut, one of which was H&E stained. Photomicrographs of these six H&E slides were marked for 300-μm diameter histologic regions of interest (Fig. 5a). Corresponding tissue sections for mass spectrometry analysis were deparaffinized and subjected to heat-induced antigen retrieval. Coordinates of the histological annotations were transferred to an acoustic robotic microspotter for deposition of trypsin and α-cyano-4-hydroxycinnamic acid matrix (10 mg/ml in 50:49.9:0.1 acetonitrile:water:trifluoroacetic acid) onto corresponding unstained serial sections. Spectra were collected using a Bruker AutoFlex Speed mass spectrometer equipped with a SmartBeam™ laser (Bruker Daltonics, Billerica, MA). Each spectrum was the sum of 1,600 laser shots collected throughout the entire area of each matrix spot. The data were preprocessed (baseline subtraction, noise level estimation and alignment to common peaks). Data were statistically analyzed using ClinPro Tools statistical analysis software package (Bruker Daltonics). Peak picking was performed manually to assure proper peak boundaries and selection of only the monoisotopic peak. Unsupervised clustering and principal component analysis were performed to classify peptide spectra in KWT and NAWT. To control for differences in peptide spectra between histologic compartments, comparisons were made between specific cell compartments only (e.g., blastema versus blastema; Fig. 5a). All experiments were completed in duplicate.

Results

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Clinical features of WTs

Gender, age at diagnosis, COG stage at presentation, disease relapse and vital status are reported for the patients with KWT and compared to NAWT controls as shown in Table 1. For the KWT specimens, obtaining complete patient data was rendered difficult because of incomplete medical records and a majority of patients having been lost to follow-up. Three of 15 patients with KWT (20%) received postoperative follow-up and were documented to be alive in the year before our study was initiated (Table 1). There are no known survivors of disease relapse among the patients with KWT. Of those patients who had documented disease relapse, two are known to be dead, whereas two others were lost to follow-up and are presumed dead. Using available data, a conservative estimate of survival among patients with KWT is 44%, and the rate of known disease relapse was 50% (Table 1).

Table 1. Demographic, histologic, and molecular features of KWT
inline image

Only one of 20 (5%) patients with NAWT was lost to follow-up (Table 1). Excluding documented mortalities and unavailable data, we detected significant differences in loss to follow-up (p = 0.028) between patients with KWT and NAWT (Table 1). Excluding patients for whom clinical details were not available, we detected significant differences in disease relapse (p = 0.044) and mortality (p = 0.001) between patients with KWT and controls (Table 1). No differences were detected in age at diagnosis or gender between the groups.

Histologic features of aggressive disease

Of the 15 KWT specimens analyzed, two patients (13%) were determined to have diffuse anaplasia (unfavorable histology; Figs. 1c and 1d). Nuclear unrest was present in eight of 13 (61.5%) favorable histology KWT specimens, but only in one of 19 (5.6%) favorable histology NAWT (p = 0.001; Fig. 1b). Blastemal predominance was present in eight of 15 WT specimens (53.3%; Fig. 1a), a rate that was similar to controls (45%; Table 1).

thumbnail image

Figure 1. Favorable and unfavorable histology Kenyan WT. (a) Favorable histology WT showing monophasic blastemal predominance (×400). (b) Triphasic favorable histology WT with nuclear unrest (×400). (c) WT from Patient 3 shows diffuse anaplasia with hyperchromatic nuclei and nuclear gigantism (×600). (d) WT from Patient 15 shows diffuse anaplasia, displaying hallmark multipolar mitoses (arrowhead) and nuclear gigantism (×600). (e) Nuclear detection of p53 in favorable histology triphasic WT (×400). Detection is present in both blastema and epithelia, but not in stroma. p53 detection was more sparse and less intense in favorable histology specimens compared to unfavorable histology. (f) Nuclear p53 detection in unfavorable histology WT from Patient 15 (×400).

Download figure to PowerPoint

Markers of treatment resistance and poor prognosis (p53/Ki67)

Immunoperoxidase staining detected p53 in 40% of KWT specimens (Table 1) and was most intense and extensive in the two unfavorable histology specimens (Fig. 1f). p53 was also detected in four favorable histology KWT, but was considerably less widespread and intense compared to unfavorable histology (Table 1 and Fig. 1e). Because of incomplete clinical outcome data, we were unable to correlate p53 positivity with stage of disease at diagnosis, disease-relapse or last known vital status (Table 1). We did not detect a difference in p53 immunopositivity between KWT specimens and NAWT controls (p = 1.00; Table 1).

A proliferative index was estimated by the percent of blastemal or epithelial Ki67 positive cells averaged over five high-power fields for both KWT specimens and NAWT controls (Table 1). Fourteen of 15 (93%) KWT specimens had estimated proliferative indices >5%, and eight of 15 (53%) KWT specimens had estimated proliferative indices >20% (Table 1). For NAWT, 17 of 20 (85%) of tumors had estimated proliferative indices > 5%, and 12 of 20 (60%) had estimated proliferative indices >20% (Table 1). The mean proliferative index was trivially higher (0.28) in KWT specimens compared to NAWT controls (0.23; p = 0.79; Table 1).

β-Catenin presence and subcellular localization

All 15 KWT specimens exhibited strong β-catenin immunostaining (Fig. 2 and Table 1). Nuclear detection of β-catenin was present in 14 of 15 KWT specimens (93%; Table 1) and was present in both favorable and unfavorable histology specimens (Fig. 2). In 13 of 15 (86.7%) KWT specimens, nuclear β-catenin was detected in the blastemal compartment. Nuclear β-catenin was detected in the epithelial compartment in 10 of 15 (66.7%) KWT specimens. There was often significant heterogeneity within each tumor specimen, and nuclear positive β-catenin was sometimes limited to very discrete areas of blastema or epithelia (<10% of cells). KWT β-catenin staining, as stratified by favorable histology, nuclear unrest and unfavorable histology, is shown in Figure 2. No difference was detected in percentage of blastemal nuclear β-catenin between KWT and controls (p = 0.560); however, a significant difference was detected in epithelial nuclear β-catenin positivity (66.7% KWT nuclear positive, 20.0% NAWT controls; p = 0.013; Table 1).

thumbnail image

Figure 2. β-Catenin expression patterns in Kenyan WT. (a) β-Catenin expression in blastemal and epithelial elements of favorable histology triphasic WT (×100). (b) High-power photomicrograph of same specimen shows nuclear detection in blastemal elements and membrane detection in epithelial elements (×400). (c and d) β-Catenin expression in two different specimens of favorable histology having nuclear unrest (×400). β-Catenin is richly detected in the nucleus of blastema and is mixed between the nucleus and membrane of epithelial elements. (e and f) β-Catenin shows rich nuclear expression in blastema of unfavorable histology WT (×200 and ×400).

Download figure to PowerPoint

Mutational analysis of CTNNB1 and WT1

Sequencing exons 3, 7 and 8 of the CTNNB1/β-catenin gene revealed wild-type β-catenin in all 15 KWT specimens (Table 1 and Fig. 3a). As CTNNB1 and WT1 mutations often cluster in WT, we also performed a mutational analysis of WT1 in these specimens. A single WT contained a homozygous nonsense mutation at position 1,244 of exon 7 (Fig. 3b), which resulted in a transition from an arginine to a stop codon (p.Arg352X; c.1244 C>T). This mutation was not detected in adjacent areas of normal kidney (Fig. 3c). A synonymous single nucleotide polymorphism (SNP; rs2234590) was detected at a single position of exon 6 in three specimens (Specimens 2, 5 and 15; Table 1): p.Gln336Gln; c.1198 A>G. Additionally, a synonymous SNP (rs16754) was detected in exon 7 of Specimen 5 (Table 1): p.Arg352Arg; c.1246 A>G.

thumbnail image

Figure 3. Mutational analysis of CTNNB1 and WT1 in Kenyan WT. (a) Despite high levels of β-catenin nuclear expression, mutational analysis revealed wild-type β-catenin in all cases at exons 3, 7 and 8. The wild-type sequence coding Serine 45 (S45), a critical phosphorylation residue in exon 3, is highlighted. (b) A single mutation (p.Arg352X; c.1244 C>T) predicted to alter the function of WT1 was detected in Specimen 10. The homozygous C to T mutation responsible for conversion of arginine to a stop codon is highlighted. (c) The wild-type sequence corresponding to (b) was detected in adjacent areas of normal kidney.

Download figure to PowerPoint

Expression of embryonic nephronic progenitor markers

WT1 was detected by immunohistochemistry in 100% of KWT specimens (Figs. 4a4d). Staining was predominantly nuclear and exclusively in the blastemal and epithelial compartments of tumors (Figs. 4a4d). CITED1 was detected in 80% of KWT overall. About 66% of tumors showed intense blastemal CITED1 staining, whereas 47% had epithelial CITED1 staining (Figs. 4e4h). CITED1 was detected exclusively in the epithelial compartment of two specimens. Epithelial staining overall was more frequently cytosolic and was less intense than blastemal staining. SIX2 was detected in 80% of KWT specimens, predominantly labeling the blastemal compartment (Figs. 4i4l). In four of 15 (27%) KWT specimens, SIX2 expression was detected in the epithelial compartment of tumors; all tumors with epithelial SIX2 positivity also showed blastemal SIX2 positivity. CITED1 and SIX2 staining patterns overlapped considerably (Figs. 4f4l); however, rare circumstances were observed in which blastema expressed CITED1 or SIX2, but not both. A summary of WT1, CITED1 and SIX2 staining in KWT is included in Table 1.

thumbnail image

Figure 4. Expression of nephronic progenitor markers in Kenyan WT. WT1 expression in favorable histology (a and b) and unfavorable histology (c and d) triphasic WT (×200 and ×400). CITED1 expression in favorable histology (e and f) and unfavorable histology (g and h) triphasic WT (×200 and ×400). SIX2 expression in triphasic WTs with favorable histology (i and j) and unfavorable histology (k and l; ×200 and ×400). Serial sections of the same favorable histology (f and j) and unfavorable histology (g and k) WTs show similar expression patterns of CITED1 and SIX2.

Download figure to PowerPoint

Imaging mass spectrometry

Unsupervised hierarchical clustering of KWT and NAWT specimens according to blastemal peptide spectra is shown in Figure 5b. This method clusters tumor specimens based on all peptide peaks collected from the blastemal compartments in each WT sample. The KWT specimens clustered distinctly with one another, yet separately from stage- and histology-matched North American specimens that were analyzed based on patient ethnicity (Fig. 5b). Principal component analysis was used to identify pairs of peptide peaks (e.g., 1,661 and 1,762 Da) that revealed distinct separation between KWT and NAWT (Fig. 5c). Black NAWT clustered closer to KWT on unsupervised hierarchical clustering (Fig. 5b) and marginally closer on principal component analysis (Fig. 5c).

thumbnail image

Figure 5. Imaging mass spectrometry analysis of Kenyan WT. (a) Image-guided selection of histologic areas of interest in two Kenyan WT specimens. To control for differences in peptide spectra between histologic compartments, comparisons were made between specific cell compartments only (e.g., blastema versus blastema; stroma versus stroma). (b) Unsupervised hierarchical clustering of peptide spectra from blastema only. Kenyan (K) WT specimens cluster together and separately from North American specimens (B, Black patient; W, White patient; numbers identify duplicate specimens from same patient with WT). (c) Principal component analysis displays two peptides detected in the blastemal compartment that distinguish Kenyan from North American WTs.

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Our study not only establishes the feasibility of conducting molecular research on WT tissues originating from a resource-constrained region of sub-Saharan Africa but also highlights the obstacles and limitations of this endeavor. Using available clinical data, immunohistochemistry, DNA sequencing and IMS, we were able to preliminarily characterize a unique and aggressive biological phenotype in WT originating from Kenya. Although these KWT specimens show many of the classical and typical features associated with this embryonal renal cancer, our findings of disease aggressiveness, treatment resistance and a distinct molecular signature suggest a unique tumor phenotype in patients native to this region, which may contribute to the high incidence and adverse behavior of WT in sub-Saharan Africa.

To explore molecular features that might contribute to the poor WT outcomes realized in this region of the world, we investigated whether this subset of KWT expressed known features of aggressive biology and treatment resistance. Diffuse anaplasia is detected in ∼5% of NAWT10 and, notably, was present in 13.3% of KWT specimens analyzed in our study. Anaplasia is more common in older children presenting with WT,10 and indeed, the two Kenyan patients having diffuse anaplasia in our study were among the oldest in the cohort. This observation perhaps implicates diagnostic and treatment delays in the accumulation of aggressive disease features in African WT. The NAWT control group was selected to contain a similar number of unfavorable histology specimens, and thus, no fair comparison can be made between these two groups in this regard. Nuclear unrest, previously reported to be present in ∼15% of WT specimens,14 was detected in 61.5% of patients with KWT and 5.6% of NAWT controls in our study. Nuclear unrest has been noted to appear in specimens with disease relapse and is thought to represent an intermediary between favorable and unfavorable histology. Although WTs with nuclear unrest have been noted to exhibit clinical features similar to favorable histology,14 the high proportion of this histologic feature in KWT is suggestive of a biological difference between this population and NAWT.

Consistent with previous reports, immunostaining for p53, a marker of unfavorable histology, was intensely detected in the two anaplastic KWT specimens examined.15 We also detected p53 in four favorable histology KWT (31% of favorable histology tumors); however, compared to diffusely anaplastic WTs, p53 positive cells were less frequent and stained less intensely in the favorable histology specimens. Although our finding of p53 accumulation in 31% of favorable histology KWT appears to contradict prior reports, these studies, such as that by Govender et al.,15 used widespread (>50%) positivity to define p53 accumulation and detected it in only three of 86 (3%) favorable histology WT specimens examined. Therefore, our results are likely consistent with prior reports. Lahoti et al.42 reported a strong association between p53 immunopositivity and metastatic or recurrent tumors. p53 accumulation in WT implies mutation of this protein and potential loss of tumor suppressor function.17, 43 We did not detect a difference in p53 expression between KWT specimens and NAWT controls. Our results suggest that unfavorable histology also correlates with p53 mutations in KWT and illustrate that p53 immunostaining is a straightforward application that can be used to identify treatment resistance in this population.

High cellular proliferation is associated with poor prognosis in WT, and Ki67 detection in more than 5% of cells has been identified as a marker of disease progression and decreased survival.18 However, that study was conducted on WT specimens having been treated with neoadjuvant chemotherapy, and the results suggest that cellular proliferation despite chemotherapy is a poor prognostic indicator. In our study, estimated proliferative index, as determined from percent Ki67 positive cellular area averaged more than 5 hpf, was greater than 5% in all except two KWT specimens analyzed. The rate of Ki67 positivity was slightly greater in patients with KWT compared to NAWT controls. Only one patient was pretreated with chemotherapy prior to resection in our control group; however, we do not know the proportion of patients who received neoadjuvant chemotherapy among the patients with KWT. Although these KWT specimens appear to express features of high cellular turnover and self-renewal compared to previous reports, the similar proliferation detected between patients with KWT and NAWT in our study emphasizes the importance of determining the patient's chemotherapy status when interpreting these numbers in WT.

In addition to markers directly linked to adverse clinical disease features, we also aimed to explore dysregulation of developmental pathways linked to Wilms' tumorigenesis. In light of all studied KWT specimens containing wild-type β-catenin by DNA sequencing of CTNNB1 exons 3, 7 and 8 (which have previously been associated with WT),20, 24 the intense detection of β-catenin and its propensity for nuclear enrichment in this cohort signify aberrant canonical Wnt signaling by another mechanism. As CTNNB1 and WT1 mutations often cluster in WT, our rate of one in 15 (6.7%) KWT specimens found to have function-altering WT1 mutations supports our findings of wild-type CTNNB1 in these specimens. The SNP rs16754 detected in Specimen 5 has been shown to correlate with higher WT1 mRNA expression and may have prognostic significance in pediatric acute myeloid leukemia; however, its role in WT has not been previously studied.44 Furthermore, the SNP rs2234590 detected in three specimens in the our study has been associated with focal segmental glomerulosclerosis in the African American population.45 All KWT specimens in our study strongly expressed β-catenin, and 93% of tumors showed nuclear localization. Although nuclear positive cells were predominantly located in the blastemal compartment of these KWT, which was not different from NAWT controls, we detected a markedly increased proportion (66.7%) of tumors showing epithelial nuclear β-catenin in KWT specimens. Notably, Koesters et al. detected nuclear β-catenin in 56% of WT examined. One-third of tumors examined in their study showed β-catenin mutations in exon 3, and all of these tumors revealed nuclear localization of β-catenin. However, the majority of tumors having nuclear positive staining harbored wild-type nuclear β-catenin, signifying β-catenin stabilization via canonical Wnt pathway activation.20 They noted nuclear positivity in approximately 5–10% of cells per tumor and only detected nuclear β-catenin in the epithelial compartment of one of 36 tumors. Our results differ from those and also from our control group observations in that we detected nuclear β-catenin in the epithelial compartment of 10 of 15 KWT specimens. The high incidence of nuclear β-catenin and its increased frequency of detection in the epithelial compartment of these Kenyan specimens suggest a unique biology related to constitutive Wnt signaling pathway activation.

The African WT specimens in our study showed widespread expression of WT1, CITED1 and SIX2, factors that label a population of self-renewing nephronic progenitor cells in kidney development. We have previously shown that increased expression of CITED1 in untreated, favorable histology WT correlates with advanced stages of disease.35 The presence of WT1 immunopositivity is found in both WT1 wild-type and mutant tumors.46 The expression of SIX2 in WT often parallels that of CITED1 and provides an additional ontogenic link to the MM of the developing kidney.47 Taken together, broad expression of these three genes that label a self-renewing stem cell population in kidney development may also define a population of malignant cells with a stem-like phenotype and the capacity to self-renew or differentiate. These genes and their associated pathways may represent potential future targets for therapies that promote terminal differentiation of WT.

To investigate differences between KWT and NAWT beyond these described tumor markers, we used IMS. We have previously studied proteomic differences in stage- and histology-matched White and Black patients in a biological analysis of race disparities in NAWT.37 In our study, we compared the proteome of five KWT specimens to this previously established signature. Our preliminary IMS results contained herein demonstrate the feasibility of performing a proteomic analysis on FFPE tissues archived in resource-constrained regions of sub-Saharan Africa. Furthermore, unsupervised hierarchical clustering of the total collected blastemal peptide spectra demonstrated distinct separation between KWT and NAWT specimens. Principal component analysis was used to select the two peptide peaks (1,661 and 1,762 Da) that together represent the greatest statistical difference in expression between the KWT and NAWT specimens. Interestingly, North American Black patients clustered closer to Kenyan patients on unsupervised hierarchical clustering and marginally closer by principal component analysis. We can only speculate on the reason for this phenomenon; however, it may represent ethnic-specific biology in the development of WT that is conserved among patients of Black African heritage. Future areas for investigation include validating these signatures in larger patient groups and sequencing peptides that are uniquely expressed or downregulated in African WT. Such knowledge may enable detection of novel biomarkers or therapeutic targets in WT.

The incomplete clinical data in this report highlight the need for more comprehensive tumor registries and tissue repositories in resource-constrained regions of the world and principally sub-Saharan Africa. Although the clinical data are incomplete for our cohort of patients with KWT, the conservatively estimated survival rate of 44% in our study parallels previously documented outcomes in this region and continues to differ drastically from the ∼90% overall survival attainable by patients with NAWT and the 95% survival rate detected in our control group.4–7, 10 Even for children who receive chemotherapy and aggressive surgical resection, recent reports from resource-constrained regions of sub-Saharan Africa indicate poor survival (∼40%) compared to series from the developed world.8 The role of delayed presentation in the accumulation of aggressive tumor features is assumed based on knowledge of cancer biology, but remains unreported in this at-risk population until now. Whether accumulation of aggressive tumor features represents an inherent biological difference in the pathogenesis of WT in Africa or is related to a delay in diagnosis, the presence of these features at the time of initial therapy seems to warrant broader implementation of high-risk treatment protocols in this patient population.

Our results indicate that WT from sub-Saharan Africa may indeed have a more aggressive and unique biological phenotype, displaying features that associate with higher mortality, disease-relapse and treatment resistance in other regions of the world. In conclusion, we have shown the feasibility of conducting molecular research on WT in a resource-constrained region of sub-Saharan Africa, where this otherwise treatable embryonal tumor is a highly lethal childhood disease. However, considerable efforts must be made to enable translational application and potential benefit of these studies to enhance outcomes of patients with WT in Africa. Our findings not only underscore the need for more adequate therapies in this resource-constrained region but also signify that even current and standard risk protocols may undertreat this population.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

The authors thank Jamie Allen for help with sample preparation. They also acknowledge the services of the Vanderbilt Translational Pathology Shared Resource, the Vanderbilt DNA sequencing facility and the GenHunter Corporation (Nashville, TN).

References

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information
  • 1
    Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75: 218695.
  • 2
    Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10: 81526.
  • 3
    Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993; 21: 17281.
  • 4
    Kyambi JM, Kasili EG, Onyango JN, Kitonyi GW. The management of Wilms' tumour in Kenya. East Afr Med J 1981; 58: 42430.
  • 5
    Kasili EG, Kyambi JM, Onyango JN, Kitonyi GW, Owade JN, Njenga GJ. Nephroblastoma: an example of cancer curable by appropriate intervention even in developing countries. East Afr Med J 1987; 64: 82835.
  • 6
    Abdallah FK, Macharia WM. Clinical presentation and treatment outcome in children with nephroblastoma in Kenya. East Afr Med J 2001; 78: S43S47.
  • 7
    Ekenze SO, Agugua-Obianyo NE, Odetunde OA. The challenge of nephroblastoma in a developing country. Ann Oncol 2006; 17: 1598600.
  • 8
    Wilde JC, Lameris W, van Hasselt EH, Molyneux EM, Heij HA, Borgstein EG. Challenges and outcome of Wilms' tumour management in a resource-constrained setting. Afr J Paediatr Surg 2010; 7: 15962.
  • 9
    Israels T, Ribeiro RC, Molyneux EM. Strategies to improve care for children with cancer in Sub-Saharan Africa. Eur J Cancer 2010; 46: 19606.
  • 10
    Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21: 35764.
  • 11
    Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, Breslow N, Green DM. Focal versus diffuse anaplasia in Wilms tumor—new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol 1996; 20: 90920.
  • 12
    Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol 1998; 1: 7984.
  • 13
    Beckwith JB, Zuppan CE, Browning NG, Moksness J, Breslow NE. Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med Pediatr Oncol 1996; 27: 4228.
  • 14
    Hill DA, Shear TD, Liu T, Billups CA, Singh PK, Dome JS. Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer 2003; 97: 231826.
  • 15
    Govender D, Harilal P, Hadley GP, Chetty R. p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer 1998; 77: 31418.
  • 16
    Sredni ST, de Camargo B, Lopes LF, Teixeira R, Simpson A. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. Med Pediatr Oncol 2001; 37: 4558.
  • 17
    Beniers AJ, Efferth T, Fuzesi L, Granzen B, Mertens R, Jakse G. p53 expression in Wilms' tumor: a possible role as prognostic factor. Int J Oncol 2001; 18: 1339.
  • 18
    Ghanem MA, Van der Kwast TH, Sudaryo MK, Mathoera RB, van den Heuvel MM, Al-Doray AA, Nijman RM, van Steenbrugge GJ. MIB-1 (Ki-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. Clin Cancer Res 2004; 10: 5917.
  • 19
    Nusse R. Cancer. Converging on β-catenin in Wilms tumor. Science 2007; 316: 9889.
  • 20
    Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T. Nuclear accumulation of β-catenin protein in Wilms' tumours. J Pathol 2003; 199: 6876.
  • 21
    Provost E, Yamamoto Y, Lizardi I, Stern J, D'Aquila TG, Gaynor RB, Rimm DL. Functional correlates of mutations in β-catenin exon 3 phosphorylation sites. J Biol Chem 2003; 278: 317819.
  • 22
    Ehrlich D, Bruder E, Thome MA, Gutt CN, von Knebel Doeberitz M, Niggli F, Perantoni AO, Koesters R. Nuclear accumulation of β-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. Pediatr Dev Pathol 2010; 13: 18.
  • 23
    Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, D'Agati V, Licht JD, et al. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004; 165: 194353.
  • 24
    Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 2009; 28: 106375.
  • 25
    Fukuzawa R, Heathcott RW, More HE, Reeve AE. Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 2007; 60: 101316.
  • 26
    Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT. Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 2007; 316: 10436.
  • 27
    Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008; 47: 46170.
  • 28
    Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, Tycko B. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002; 160: 218190.
  • 29
    Boyle S, Shioda T, Perantoni AO, de Caestecker M. Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn 2007; 236: 232130.
  • 30
    Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, McMahon AP. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 2008; 3: 16981.
  • 31
    Hendry C, Rumballe B, Moritz K, Little MH. Defining and redefining the nephron progenitor population. Pediatr Nephrol 2011; 26: 1395406. Epub 2011 Jan 14. Review.
  • 32
    Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JBL. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1993; 40: 8597.
  • 33
    Kreidberg JA. WT1 and kidney progenitor cells. Organogenesis 2010; 6: 6170.
  • 34
    Vuononvirta R, Sebire NJ, Dallosso AR, Reis-Filho JS, Williams RD, Mackay A, Fenwick K, Grigoriadis A, Ashworth A, Pritchard-Jones K, Brown KW, Vujanic GM, et al. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res 2008; 14: 763544.
  • 35
    Lovvorn HN, Westrup J, Opperman S, Boyle S, Shi G, Anderson J, Perlman EJ, Perantoni AO, Wills M, de Caestecker M. CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia 2007; 9: 589600.
  • 36
    Groseclose MR, Massion PP, Chaurand P, Caprioli RM. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008; 8: 371524.
  • 37
    Axt J, Murphy AJ, Seeley EH, Martin CA, Taylor C, Pierce J, Caprioli RM, Whiteside M, Lovvorn HN. Race disparities in Wilms tumor incidence and biology. J Surg Res 2011; 170: 11219.
  • 38
    Wegert J, Bausenwein S, Roth S, Graf N, Geissinger E, Gessler M. Characterization of primary Wilms tumor cultures as an in vitro model. Genes Chromosomes Cancer 2012; 51: 92104.
  • 39
    Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a children's oncology group study. J Clin Oncol 2011; 29: 698703.
  • 40
    Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, Mora J, Brandt A, Royer HD. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Hum Mol Genet 2010; 19: 165168.
  • 41
    Seeley EH, Caprioli RM. Molecular imaging of proteins in tissues by mass spectrometry. Proc Natl Acad Sci USA 2008; 105: 1812631.
  • 42
    Lahoti C, Thorner P, Malkin D, Yeger H. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol 1996; 148: 157789.
  • 43
    Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7: 917.
  • 44
    Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol 2011; 29: 70411.
  • 45
    Orloff MS, Iyengar SK, Winkler CA, Goddard KA, Dart RA, Ahuja TS, Mokrzycki M, Briggs WA, Korbet SM, Kimmel PL, Simon EE, Trachtman H, et al. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics 2005; 21: 21221.
  • 46
    Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 2011; 121: 17483.
  • 47
    Murphy AJ, Pierce J, de Caestecker C, Taylor C, Anderson JR, Perantoni AO, de Caestecker MP, Lovvorn HN. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms tumor. J Pediatr Surg, in press.

Supporting Information

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
IJC_27544_sm_SuppTab1.doc69KSupporting Information
IJC_27544_sm_SuppTab2.doc39KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.